Bolt Biotherapeutics, Inc. (NASDAQ:BOLT) Short Interest Down 83.8% in December

Bolt Biotherapeutics, Inc. (NASDAQ:BOLT) was the target of a significant decline in short interest during the month of December. As of December 31st, there was short interest totaling 352 shares, a decline of 83.8% from the December 15th total of 2,177 shares. Based on an average daily volume of 32,280 shares, the days-to-cover ratio is currently 0.0 days. Currently, 0.0% of the shares of the stock are sold short. Currently, 0.0% of the shares of the stock are sold short. Based on an average daily volume of 32,280 shares, the days-to-cover ratio is currently 0.0 days.

Bolt Biotherapeutics Trading Down 0.3%

Shares of Bolt Biotherapeutics stock traded down $0.02 on Monday, hitting $5.81. The stock had a trading volume of 13,234 shares, compared to its average volume of 22,951. The company has a quick ratio of 3.57, a current ratio of 3.57 and a debt-to-equity ratio of 0.65. Bolt Biotherapeutics has a one year low of $4.41 and a one year high of $11.70. The stock’s 50-day simple moving average is $5.21 and its two-hundred day simple moving average is $5.47. The stock has a market cap of $11.16 million, a price-to-earnings ratio of -0.26 and a beta of 0.91.

Bolt Biotherapeutics (NASDAQ:BOLT) last posted its quarterly earnings results on Wednesday, November 12th. The company reported ($3.72) EPS for the quarter, beating analysts’ consensus estimates of ($5.07) by $1.35. The firm had revenue of $2.17 million for the quarter, compared to the consensus estimate of $0.82 million. As a group, sell-side analysts predict that Bolt Biotherapeutics will post -1.61 EPS for the current year.

Analysts Set New Price Targets

Several analysts have recently weighed in on BOLT shares. Weiss Ratings restated a “sell (e+)” rating on shares of Bolt Biotherapeutics in a research report on Wednesday, October 8th. Zacks Research cut Bolt Biotherapeutics from a “strong-buy” rating to a “hold” rating in a research note on Thursday, November 20th. Finally, HC Wainwright set a $7.00 price target on Bolt Biotherapeutics and gave the company a “buy” rating in a research report on Monday, October 20th. Two research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus price target of $34.00.

Institutional Trading of Bolt Biotherapeutics

Large investors have recently modified their holdings of the business. Squarepoint Ops LLC raised its position in Bolt Biotherapeutics by 19.8% during the 3rd quarter. Squarepoint Ops LLC now owns 14,836 shares of the company’s stock valued at $79,000 after purchasing an additional 2,448 shares during the last quarter. Shay Capital LLC bought a new stake in shares of Bolt Biotherapeutics in the 3rd quarter worth approximately $85,000. Finally, Susquehanna International Group LLP purchased a new position in shares of Bolt Biotherapeutics during the third quarter valued at approximately $89,000. 86.70% of the stock is owned by institutional investors.

About Bolt Biotherapeutics

Bolt Biotherapeutics is a clinical-stage immuno-oncology company focused on developing novel targeted therapies that engage both innate and adaptive immune responses against cancer. The company’s proprietary Biologics-Driven Checkpoint (BDC) platform combines tumor-targeting antibodies with innate immune agonists to activate antigen-presenting cells within the tumor microenvironment, thereby promoting robust T-cell mediated tumor cell killing. Its lead candidate, BDC-1001, couples a HER2-directed monoclonal antibody with a Toll-like receptor 7/8 agonist and is currently in Phase I clinical trials for HER2-positive solid tumors.